Recent News for LGVN - Longeveron Inc.

Date Title
Apr 15 Longeveron completes Phase I/II Lomecel-B influenza vaccine study
Apr 15 Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination
Apr 13 Longeveron (LGVN) shares surge 26% on positive Lomecel-B results in Alzheimer’s disease
Apr 13 Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease
Apr 12 SmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech Titan
Mar 30 Longeveron's (LGVN) CEO Geoff Green on Q4 2020 Results - Earnings Call Transcript
Mar 30 Longeveron shares rise after Q4 results, business update
Mar 30 Longeveron reports Q4 results
Mar 30 Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 30 Earnings Scheduled For March 30, 2021
Mar 26 Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call
Mar 26 The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
Mar 19 Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24
Mar 15 Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
Mar 12 The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs
Mar 11 Longeveron climbs on FDA’s compassionate use approval for Lomecel-B
Mar 11 Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)
Mar 10 Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations
Mar 5 Longeveron expands enrollment criteria in early-stage ARDS trial
Mar 5 Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza Infection
Mar 3 Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty
Feb 24 Longeveron completes early-stage Lomecel-b heart defect study
Feb 24 Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients
Feb 19 CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology
Feb 18 Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board of Directors
Back to the Main LGVN Page...